Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder
Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder
复制标题
DOI：
10.1016/j.janxdis.2007.03.001
复制
发表时间：
2008-01-01
影响因子：
10.3
通讯作者：
Randall, Carrie L.
中科院分区：
文献类型：
--
作者：
Book, Sarah W.;Thomas, Suzanne E.;Randall, Carrie L.
在临床实践中发现的社交焦虑障碍患者通常有其他精神病合并症，包括酒精使用障碍。社交焦虑症的一线治疗是选择性5-羟色胺再摄取抑制剂（SSRIs），如帕罗西汀。然而，SSRIs的疗效是通过排除酗酒者的研究确定的。42名社交焦虑和合并酒精使用障碍的受试者参加了一项为期16周的双盲安慰剂对照临床试验，以确定帕罗西汀对合并酒精问题的社交焦虑患者的疗效。帕罗西汀在减少社交焦虑方面上级安慰剂，如通过Liebowitz社交焦虑量表总分和子量表评分以及社交焦虑的附加测量所测量的。这项研究提供了第一个基于证据的建议，使用SSRI来治疗这一患者人群的社交焦虑。(C)2007爱思唯尔有限公司保留所有权利。
Patients with social anxiety disorder who are seen in clinical practice commonly have additional psychiatric comorbidity, including alcohol use disorders. The first line treatment for social anxiety disorder is selective-serotonin-reuptake-inhibitors (SSRIs), such as paroxetine. However, the efficacy of SSRIs has been determined with studies that excluded alcoholics. Forty two subjects with social anxiety and a co-occurring alcohol use disorder participated in a 16-week, double-blind, placebo-controlled clinical trial to determine the efficacy of paroxetine for social anxiety in patients with co-occurring alcohol problems. Paroxetine was superior to placebo in reducing social anxiety, as measured by the Liebowitz Social Anxiety Scale total and subscale scores and additional measures of social anxiety. This study provides the first evidence-based recommendation for the use of an SSRI to treat social anxiety in this patient population. (C) 2007 Elsevier Ltd. All rights reserved.